AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool.
Fiche publication
Date publication
février 2023
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe
Tous les auteurs :
Piñero F, Costentin C, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas A, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Duque SH, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Carrilho F, Cherqui D, Burra P, Van Vlierberghe H, Lai Q, Silva M, Rubinstein F, Duvoux C, , , , ,
Lien Pubmed
Résumé
Two recently developed composite models, the alpha-fetoprotein (AFP) score and Metroticket 2.0, could be used to select patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation (LT). The aim of this study was to compare the predictive performance of both models and to evaluate the net risk reclassification of post-LT recurrence between them using each model's original thresholds.
Mots clés
AFP, alpha-fetoprotein, HCC, hepatocellular carcinoma, HR, hazard ratio, LT, liver transplantation, NRI, net reclassification index, Prediction, SHR, sub-hazard ratio, reclassification, recurrence, transplantation
Référence
JHEP Rep. 2023 02;5(2):100644